Literature DB >> 18534880

Clinical trial of patching versus atropine penalization for the treatment of anisometropic amblyopia in older children.

Vimla Menon1, Gadaginamath Shailesh, Pradeep Sharma, Rohit Saxena.   

Abstract

PURPOSE: To compare conventional patching therapy with atropine penalization in the treatment of anisometropic amblyopia.
METHODS: Prospective, randomized, institution-based clinical trial of patching versus atropine penalization in patients aged 8-20 years. Patients received either conventional, full-time patching, or atropine penalization.
RESULTS: Fifty-seven patients were enrolled, with visual acuity ranging from 6/12 to 6/60 in the amblyopic eye. Twenty-nine patients received conventional full-time patching; 28 received atropine penalization. At 6 months, visual acuity improved by 2.38 lines in the conventional patching group and 2.34 lines in the atropine group (p = 0.889). The speed of visual recovery was faster in the patching group (3.7 months) than in the atropine group (4.7 months; p = 0.013). There was significant improvement in near vision and contrast sensitivity in both groups, but improvement in the patching group was significantly better than in the atropine group. No patient had reduced visual acuity in the unaffected eye. Redness of eyes was observed more in the atropine group than in the patching group. Treatment tended to be better-accepted by parents and patients in the atropine group, but not significantly more.
CONCLUSIONS: In patients aged 8-20 years with anisometropic amblyopia, both patching and atropine therapy improved visual acuity. Although recovery was faster with patching, the 2 modalities of treatment appeared to be equally effective.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18534880     DOI: 10.1016/j.jaapos.2008.03.006

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  12 in total

Review 1.  Amblyopia.

Authors:  Stephanie West; Cathy Williams
Journal:  BMJ Clin Evid       Date:  2011-06-30

Review 2.  The treatment of amblyopia: current practice and emerging trends.

Authors:  Eleni Papageorgiou; Ioannis Asproudis; Gail Maconachie; Evangelia E Tsironi; Irene Gottlob
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-01-31       Impact factor: 3.117

3.  Conventional occlusion versus pharmacologic penalization for amblyopia.

Authors:  Tianjing Li; Riaz Qureshi; Kate Taylor
Journal:  Cochrane Database Syst Rev       Date:  2019-08-28

4.  Characterization of Bangerter filter effect in mild and moderate anisometropic amblyopia: predictive factors for the visual outcome.

Authors:  Carlos Laria; David P Piñero; Jorge L Alió
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-11-19       Impact factor: 3.117

5.  Efficacy of interventions for amblyopia: a systematic review and network meta-analysis.

Authors:  Yonghong Li; Huan Sun; Xiaojuan Zhu; Yana Su; Tianqi Yu; Xinyu Wu; Xiaoqin Zhou; Li Jing
Journal:  BMC Ophthalmol       Date:  2020-05-25       Impact factor: 2.209

Review 6.  The challenges of amblyopia treatment.

Authors:  Gail D E Maconachie; Irene Gottlob
Journal:  Biomed J       Date:  2016-02-28       Impact factor: 4.910

Review 7.  Atropine Penalization Versus Occlusion Therapies for Unilateral Amblyopia after the Critical Period of Visual Development: A Systematic Review.

Authors:  Daniel C Osborne; Kathryn M Greenhalgh; Megan J E Evans; Jay E Self
Journal:  Ophthalmol Ther       Date:  2018-10-16

Review 8.  Simplified updates on the pathophysiology and recent developments in the treatment of amblyopia: A review.

Authors:  Santhan K S Gopal; Jai Kelkar; Aditya Kelkar; Abhishek Pandit
Journal:  Indian J Ophthalmol       Date:  2019-09       Impact factor: 1.848

Review 9.  Management of amblyopia in pediatric patients: Current insights.

Authors:  Sagnik Sen; Pallavi Singh; Rohit Saxena
Journal:  Eye (Lond)       Date:  2021-07-07       Impact factor: 3.775

Review 10.  Conventional occlusion versus pharmacologic penalization for amblyopia.

Authors:  Tianjing Li; Kate Shotton
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.